Differentiated product
Sucroferric oxyhydroxide
Tablet (differentiated) · Hyperphosphataemia in CKD
Product data
- Dosage form
- Tablet (differentiated)
- Dosage-form group
- Oral solid
- Therapeutic area
- Hyperphosphataemia in CKD
- Reference product
- Tablet 500 mg
- Status
- Ready for technology transfer
- Development stage
- 4 of 5 · Ready for tech transfer
- Portfolio
- Differentiated product
Start a conversation
Where does your programme stand?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.
Business enquiries: vasanthi@kmshc.com · +91 97898 75194V-23